



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/684,361	10/06/2000	Alexander Gaiger	210121.465C2	9832
500 7	11/29/2005	EXAMINER		
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE			SCHWADRON, RONALD B	
SUITE 6300	SUITE 6300			PAPER NUMBER
SEATTLE, W	A 98104-7092		1644	

DATE MAILED: 11/29/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No	. Applicant(s)				
		09/684,361	GAIGER ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Ron Schwadron	, Ph.D. 1644				
Period fo	The MAILING DATE of this communication Reply	on appears on the cove	r sheet with the correspondence a	nddress			
WHIC - Exte after - If NC - Failt Any	ORTENED STATUTORY PERIOD FOR INCHEVER IS LONGER, FROM THE MAILLI INSIGNS of time may be available under the provisions of 37 of SIX (6) MONTHS from the mailing date of this communicat of period for reply is specified above, the maximum statutory tre to reply within the set or extended period for reply will, by reply received by the Office later than three months after the departent term adjustment. See 37 CFR 1.704(b).	NG DATE OF THIS CO CFR 1.136(a). In no event, how tion. period will apply and will expire y statute, cause the application	OMMUNICATION. vever, may a reply be timely filed SIX (6) MONTHS from the mailing date of this to become ABANDONED (35 U.S.C. § 133).				
Status							
1)	Responsive to communication(s) filed on						
- '=		· 【This action is non-fin	al				
3)				ne merite is			
٠,٠	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims	The Large Quayre,					
_		in the application					
	Claim(s) 1.6,7 and 47-51 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
	Claim(s) <u>1,6 and 7</u> is/are allowed.						
7)□	Claim(s) 47-51 is/are rejected.						
•=	Claim(s) is/are objected to.	and/an alastian na min	· · 4				
0)□	Claim(s) are subject to restriction	and/or election require	ment.				
Applicat	on Papers						
9)[The specification is objected to by the Exa	aminer.					
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)	The oath or declaration is objected to by t	he Examiner. Note the	attached Office Action or form P	PTO-152.			
Priority ι	ınder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the priority documents have been received in this National Stage						
	application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.							
Attachmen	c(s)						
	e of References Cited (PTO-892)	4) 🗍	Interview Summary (PTO-413)				
2) Notic	e of Draftsperson's Patent Drawing Review (PTO-94	·8)	Paper No(s)/Mail Date				
Inform [] (c Pape	nation Disclosure Statement(s) (PTO-1449 or PTO/S No(s)/Mail Date		Notice of Informal Patent Application (PT Other:	O-152)			

- 1. Claims 1,6,7,47-51 are under consideration.
- The following is a quotation of the first paragraph of 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 3. The rejection of claims 57,59,60,63 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement for the reasons elaborated in the previous Office action is withdrawn in view of the cancellation of said claims.
- 4. The rejection of claims 6 and 7 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for the reasons elaborated in the previous Office Action is withdrawn in view of the amended claims.
- 5. The rejection of claims 57,59,60,63 under 35 U.S.C. 103(a) as obvious over Herlyn et al. (WO 95/29995) in view of Jager et al. (US Patent 6,096,313). Herlyn et al. for the reasons elaborated in the previous Office Action is withdrawn in view of the cancellation of said claims.
- 6. Claims 47-51 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There is no support in the specification as originally filed for the "composition" of claim 47 or the immunogenic compositions of claims 48-51. While the specification discloses vaccines with the ingredients recited in claims 48-51(eg. non-specific immune response enhancer), there is no disclosure of non-vaccine compositions in the specification as originally filed which contain a non-specific immune response enhancer. These two terms differ in scope in that the art recognizes that a vaccine is

used for treatment of disease, including human disease, while the term immunogenic composition does not necessarily imply that the composition would be used to treat human disease. Regarding claim 47, whilst the specification discloses a pharmaceutical composition with the ingredients recited in claim 47, it does not disclose a composition per se with said ingredient. These two terms differ in scope in that the art recognizes that a pharmaceutical composition is used for treatment of disease, including human disease, while the term composition does not necessarily imply that the composition would be used to treat human disease.

There is no support in the specification as originally filed for the scope of the claimed invention (eg. the claimed invention constitutes new matter).

- 10. Claims 1,6 and 7 are allowed.
- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ron Schwadron, Ph.D. whose telephone number is 571 272-0851. The examiner can normally be reached on Monday-Thursday 7:30-6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RONALD B. SCHWADRON PRIMARY EXAMINER GROUP 1960 (600

Ron Schwadron, Ph.D. Primary Examiner Art Unit 1644